Abstract
The
characterization
of
circulating
tumor
cells
(CTCs)
holds
promises
for
precision
medicine
because
these
are
an
important
clinical
indicator
treatment
efficacy.
We
established
the
first
and
still
only
nine
permanent
colon
CTC
lines
from
peripheral
blood
samples
a
patient
with
metastatic
cancer
collected
at
different
time
points
during
progression.
study
objectives
were
(
i
)
to
compare
gene
expression
profiles
lines,
ii
determine
main
features
acquired
treatment.
number
upregulated
genes
was
higher
in
obtained
after
treatment,
indicating
that
they
properties
escape
pressure.
Among
genes,
some
involved
mTOR
PI3K/AKT
signaling
pathways.
Moreover,
cytidine
deaminase
significantly
increased
failure
first-
second-line
5-fluorouracile-based
treatments,
suggesting
CTCs
can
eliminate
this
specific
drug
resist
therapy.
Several
enzymes
xenobiotic
metabolism
also
activation
detoxification
mechanisms
response
chemotherapy.
Finally,
significant
aldolase
B
four
six
withdrawal
progression
indicated
clones
originated
liver
metastases.
In
conclusion,
generated
single
characterized
by
deregulation
promote
resistance,
energy
metabolism,
iii
stem
cell
plasticity.
Cancer Discovery,
Год журнала:
2021,
Номер
11(4), С. 858 - 873
Опубликована: Апрель 1, 2021
Over
the
past
10
years,
circulating
tumor
cells
(CTC)
and
DNA
(ctDNA)
have
received
enormous
attention
as
new
biomarkers
subjects
of
translational
research.
Although
both
are
already
used
in
numerous
clinical
trials,
their
utility
is
still
under
investigation
with
promising
first
results.
Clinical
applications
include
early
cancer
detection,
improved
staging,
detection
relapse,
real-time
monitoring
therapeutic
efficacy,
targets
resistance
mechanisms.
Here,
we
propose
a
conceptual
framework
CTC
ctDNA
assays
point
out
current
challenges
research,
which
might
structure
this
dynamic
field
SIGNIFICANCE:
The
analysis
blood
for
CTCs
or
cell-free
nucleic
acids
called
"liquid
biopsy"
has
opened
avenues
diagnostics,
including
tumors,
risk
assessment
well
relapse
evolution
context
therapies.
Signal Transduction and Targeted Therapy,
Год журнала:
2024,
Номер
9(1)
Опубликована: Окт. 11, 2024
The
cascade
of
metastasis
in
tumor
cells,
exhibiting
organ-specific
tendencies,
may
occur
at
numerous
phases
the
disease
and
progress
under
intense
evolutionary
pressures.
Organ-specific
relies
on
formation
pre-metastatic
niche
(PMN),
with
diverse
cell
types
complex
interactions
contributing
to
this
concept,
adding
a
new
dimension
traditional
cascade.
Prior
metastatic
dissemination,
as
orchestrators
PMN
formation,
primary
tumor-derived
extracellular
vesicles
prepare
fertile
microenvironment
for
settlement
colonization
circulating
cells
distant
secondary
sites,
significantly
impacting
cancer
progression
outcomes.
Obviously,
solely
intervening
sites
passively
after
macrometastasis
is
often
insufficient.
Early
prediction
holistic,
macro-level
control
represent
future
directions
therapy.
This
review
emphasizes
dynamic
intricate
systematic
alterations
that
progresses,
illustrates
immunological
landscape
creation,
deepens
understanding
treatment
modalities
pertinent
metastasis,
thereby
identifying
some
prognostic
predictive
biomarkers
favorable
early
predict
occurrence
design
appropriate
combinations.
Molecular Aspects of Medicine,
Год журнала:
2024,
Номер
96, С. 101258 - 101258
Опубликована: Фев. 21, 2024
Over
the
past
decade,
novel
methods
for
enrichment
and
identification
of
cancer
cells
circulating
in
blood
have
been
established.
Blood-based
detection
other
tumor-associated
products
can
be
summarized
under
term
Liquid
Biopsy.
Circulating
tumor
(CTCs)
used
diagnosis,
risk
stratification
treatment
selection
as
well
monitoring
several
studies
over
years,
thus
representing
a
valuable
biomarker
patients.
A
plethora
to
enrich,
detect
analyze
CTCs
has
In
contrast
liquid
biopsy
analytes
(e.g.
ctDNA),
represent
viable
analyte
that
provides
unique
opportunity
understand
underlaying
biology
metastatic
cascade
on
molecular
level.
this
review,
we
provide
an
overview
current
enrichment,
detection,
functional
characterization
CTCs.
Abstract
Circulating
tumor
cells
(CTCs)
drive
metastasis,
the
leading
cause
of
death
in
individuals
with
breast
cancer.
Due
to
their
low
abundance
circulation,
robust
CTC
expansion
protocols
are
urgently
needed
effectively
study
disease
progression
and
therapy
responses.
Here
we
present
establishment
long-term
CTC-derived
organoids
from
female
metastatic
Multiomics
analysis
along
preclinical
modeling
xenografts
identified
neuregulin
1
(NRG1)–ERBB2
receptor
tyrosine
kinase
3
(
ERBB3
/HER3)
signaling
as
a
key
pathway
required
for
survival,
growth
dissemination.
Genome-wide
CRISPR
activation
screens
revealed
that
fibroblast
factor
(FGFR1)
serves
compensatory
function
NRG1–HER3
axis
rescues
NRG1
deficiency
CTCs.
Conversely,
induced
resistance
FGFR1
inhibition,
whereas
combinatorial
blockade
impaired
growth.
The
dynamic
interplay
between
reveals
molecular
basis
cancer
cell
plasticity
clinically
relevant
strategies
target
it.
Our
organoid
platform
enables
identification
validation
patient-specific
vulnerabilities
represents
an
innovative
tool
precision
medicine.
Cells,
Год журнала:
2020,
Номер
9(8), С. 1836 - 1836
Опубликована: Авг. 5, 2020
In
the
last
few
decades,
epithelial
cell
adhesion
molecule
(EpCAM)
has
received
increased
attention
as
main
membrane
marker
used
in
many
enrichment
technologies
to
isolate
circulating
tumor
cells
(CTCs).
Although
there
been
a
great
deal
of
progress
implementation
EpCAM-based
CTC
detection
medical
settings,
several
issues
continue
limit
their
clinical
utility.
The
biology
EpCAM
and
its
role
are
not
completely
understood
but
evidence
suggests
that
expression
this
cell-surface
protein
is
crucial
for
metastasis-competent
CTCs
may
be
lost
during
epithelial-to-mesenchymal
transition.
review,
we
summarize
most
significant
advantages
disadvantages
using
potential
biological
metastatic
cascade.
Clinical Chemistry and Laboratory Medicine (CCLM),
Год журнала:
2021,
Номер
59(7), С. 1181 - 1200
Опубликована: Фев. 5, 2021
Despite
advances
in
screening
and
therapeutics
cancer
continues
to
be
one
of
the
major
causes
morbidity
mortality
worldwide.
The
molecular
profile
tumor
is
routinely
assessed
by
surgical
or
bioptic
samples,
however,
genotyping
tissue
has
inherent
limitations:
it
represents
a
single
snapshot
time
subjected
spatial
selection
bias
owing
heterogeneity.
Liquid
biopsy
emerged
as
novel,
non-invasive
opportunity
detecting
monitoring
several
body
fluids
instead
tissue.
Circulating
cells
(CTCs),
circulating
DNA
(ctDNA),
RNA
(mRNA
microRNA),
microvesicles,
including
exosomes
"educated
platelets"
were
recently
identified
source
genomic
information
patients
which
could
reflect
all
subclones
present
primary
metastatic
lesions
allowing
sequential
disease
evolution.
In
this
review,
we
summarize
currently
available
concerning
liquid
breast
cancer,
colon
lung
melanoma.
These
promising
issues
still
need
standardized
harmonized
across
laboratories,
before
fully
adopting
approaches
into
clinical
practice.
